Abstract
Thomas Alexander McBean died on New Year’s Day, 1846, the cause of his death being certified as atrophy from albuminuria. Clamp1 has identified this man as being the source of the specimen of urine which Dr Thomas Watson sent to Dr Henry Bence Jones on 1st November, 1845. This urine contained a substance which Bence Jones characterized according to the understanding of chemistry in the mid-nineteenth century2 and which we now know as Bence Jones protein.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Clamp, J. R. (1967). Some aspects of the first recorded case of multiple myeloma. Lancet, 2, 1354–1356
Bence Jones, H. (1848). On a new substance occurring in the urine of a patient with mollities ossium. Phil. Trans. R. Soc, 55–62
Bence Jones, H. (1847). Papers on chemical pathology. Lecture III. Lancet, 2, 88–92
Dalrymple, J. (1846). On the microscopical character of mollities ossium.Dublin J. Med. Sci., 2, 85–95
MacIntyre, W. (1850). Case of mollities et fragilitas ossium. Med. Chir. Trans., 33, 211–232
Bayrd, E. D. and Heck, F. J. (1947). Multiple myeloma. A review of 83 proved cases. J. Am. Med. Assoc, 133, 147–157
Salmon, S. E. and Seligmann, M. (1974). B-cell neoplasia in man. Lancet, 2, 1230–1233
Pierson, J., Darley, T., Stevenson, G. T. and Virji, M. (1980). Monoclonal immunoglobulin light chains in urine of patients with lymphomas. Br. J. Cancer, 41,681–688
Hobbs, J. R. (1967). Paraproteins — benign or malignant? Br. Med. J., 3, 699–704
Paladini, G., Sala, P.G. and Sautini, P.A. (1980). Benign Bence Jones gam-mopathy. Acta Haematol., 63, 241–246
Tubbs, R. R., Gephardt, G. N. and McMahon, J. T. (1981). Light chain nephropathy. Am. J. Med, 71, 263–269
Kyle, R. A. (1978). Monoclonal gammopathy of undetermined significance. Am. J. Med, 64, 814–826
Kyle, R. A. and Greipp, P. R. (1982). Idiopathic Bence Jones proteinuria. N. Engl. J. Med., 306, 564–607
Durie, B.G. M. and Salmon, S. E. (1977). Multiple myeloma, macro-globulinaemia and monoclonal gammopathies. In Hoffbrand, A.V., Brainm, M. L. and Hirsch, J. (eds.) Recent Advances in Haematology 2. (London: Churchill Livingstone)
Chronic Leukaemia-Myeloma Task Force (1973). National Cancer Institute. Proposed guidelines for protocol studies II: Plasma cell myeloma. Cancer Chemother. Rep., 4, 145–158
Parker, D. and Malpas, J. S. (1979). Multiple myeloma. J. R. Coll. Phys. London, 13, 146–153
Kyle, R. A. (1975). Multiple myeloma; a review of 869 cases. Mayo Clin. Proc, 50, 29–40
Barteloni, C, Flamini, G. and Logoscino, C. (1980). IgD kappa ‘non-secretory’ multiple myeloma. Report of a case. Blood, 56, 898–901
Kapadia, S. B. (1980). Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore), 59, 380–392
Stone, M.J. and Frenkel, E.P. (1975). The clinical spectrum of light chain myeloma. Am. J. Med, 58, 601–617
Pruzanski, W. (1976). Clinical manifestation of multiple myeloma in relation to class and type of M component. Can. Med. Assoc. J., 114, 898–897
Perry, M. and Kyle, R. A. (1975). The clinical significance of Bence Jones proteinuria. Mayo Clin. Proc, 56, 234–238
Durie, B. G. M., Cole, P. W., Chen, H. S. G. et al. (1981). Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma. Br. J. Haematol., 47, 7–19
Gallango, M.C., Swinger, R. and Ramirez, M. (1980). Bence Jones myeloma with a tetramer of kappa type globulin in serum. Clin. Chem., 26, 1741–1744
Roberts-Thompson, P. J., Venables, G.S., Onitiri, A.C. and Leavis, B. (1975). Polymeric IgA myeloma. Postgrad. Med. J., 51, 44–51
Roberts-Thompson, P.J., Mason, D.Y. and MacLennan, I.C.M. (1976). Br. J. Haematol, 33, 117–130
Shustik, C, Bergsagel, D. E. and Pruzanski, W. (1976). Kappa and lambda light chain disease: survival rates and clinical manifestations. Blood, 48, 41–51
Velez, R., Beral, V. and Cuzick, J. (1982). Increasing trends of multiple myeloma mortality in England and Wales; 1950–79 are the changes real? J. Natl. Cancer Inst., 69, 387–392
Linos, A., Kyle, R. A. and O’Fahon, L. T. (1981). Incidence and secular trend of multiple myeloma in Olmsted County, Minnesota 1965–1977. J. Natl. Cancer Inst., 66, 17–20
Blattner, W. A. (1980). Epidemiology of multiple myeloma and related plasma cell disorders. In Potter, M. (ed.) Progress in Myeloma, pp. 1–65. (New York: Elsevier)
Egan, E. L., Grimes, H. and O’Biern, D.P. (1978). Multiple myeloma in the West of Ireland, presentation and frequency. Ir. Med. J., 71, 23–26
Blattner, W.A., Blair, A. and Mason, T.J. (1981). Multiple myeloma in the United States 1950–1975. Cancer, 48, 2547–2554
Durie, B. G. M. and Salmon, S. E. (1975). A clinical staging system for multiple myeloma. Cancer 36, 842–854
Woodruff, R. K., Wadsworth, J., Malpas, J. S. and Tobias, J. S. (1979). Clinical staging in multiple myeloma. Br. J. Haematol., 42, 199–205
Salmon, S. E. and Wampler, S. B. (1978). Multiple myeloma. Quantitative staging and assessment of response with a programmable pocket calculator. Blood, 49, 379–389
Durie, B. G. M., Cole, P. W., Chen, H. S. G. et al. (1981). Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma. Br. J. Haematol., 47, 7–19
Medical Research Council (1973). Report on the first myelomatosis trial Part I. Analysis of presenting features of prognostic importance. Br. J. Haematol, 24, 123–139
Medical Research Council (1980). Prognostic features in the third MRC myelomatosis trial. Br. J. Cancer, 42, 831
Peto, R. (1971). Myeloma workshop: Urea, albumin and response rates. Br. Med. J., 1, 324
Alexanian, R., Balcerzak, S., Bonner, J. D. et al. (1975). Prognostic features of multiple myeloma. Cancer, 36, 1192–1201
Matzner, Y., Benbassat, J. and Polliack, A. (1978). Prognostic factors in multiple myeloma. Acta Haematol, 60, 257–268
Colls, B. M. and Barlow, B. A. (1979). Multiple myeloma — prognosis, treatment and survival in an 8 year study. Aust. N.Z. J. Med., 9, 262–268
Durie, B.G.M., Salmon, S. E. and Moon, T. E. (1980). Pretreatment tumour mass in multiple myeloma. Blood, 55, 364–372
Jansen, J., Huijgens, P. L. and Van der Velde, E. A. (1980). Prognosis of multiple myeloma. Neth. Med. J., 13, 246–251
Merlini, G., Waldenstrom, J.C. and Jagakar, S.D. (1980). A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood, 55, 1011–1019
Johannsson, B. (1971). Prognostic features in mvelomatosis. Br. Med. J., 1, 327-
Cornell, C. J., McIntyre, O. R., Kochwa, S. et al. (1979). Response to therapy in IgG myeloma patients excreting or light chains. CALGB experience. Blood, 54, 23–29
Graham, R. C. and Bernier, G. M. (1975). The bone marrow in multiple myeloma. Medicine (Baltimore), 54, 225–243
Latreille, J., Barlogie, B., Johnson, D. et al. (1982). Ploidy and proliferative characteristics in monoclonal gammopathies. Blood, 59, 43–51
Gassmann, W., Pralle, H., Haferlach, T. et al. (1985). Staging systems for multiple myeloma: a comparison. Br. J. Haematol, 59, 703–711
Norfolk, D.R., Child, J.A., Cooper, E.H. et al. (1980). Serum beta2 microglobulin in myelomatosis. Potential value in stratification and monitoring. Br. J. Cancer, 42, 510–515
Morrell, A. and Riesen, W. (1980). Serum beta2 microglobulin serum creatinine and bone marrow plasma cell count in benign and malignant monoclonal gammopathy. Acta Haematol., 64, 87–93
Bataille, R., Magub, M., Sany, J. et al. (1981). Beta2 microglobuline serique au cours du myelome multiple. Rev. Rheum, 48, 235–240
Bataille, R., Magub, M., Grenier, J., Donnadio, D. and Sany, J. (1981). Serum beta2 microglobulin in multiple myeloma. Relation to presenting features and clinical status. Eur. J. Cancer Clin., 18, 59–66
Child, J. A., Crawford, S. M., Norfolk, D. R. et al. (1983). Evaluation of serum beta2 microglobulin as a prognostic indicator in myelomatosis. Br. J. Cancer, 47, 111–114
Cuzick, J., Cooper, E. H. and MacLennan, I. C. M. (1985). The prognostic value of serum beta2 microglobulin compared with other presentation features in myelomatosis. Br. J. Cancer, 52, 1–6
van Dobbenburgh, O. A., Rodenhuis, S., Ockhuizen, T. et al. (1985). Serum beta2 microglobulin: a real improvement in the management of multiple myeloma? Br. J. Haematol, 61, 611–620.
Colls, B. M. and Darlow, B. A. (1979). Multiple myeloma — prognosis, treatment and survival in an 8 year study. Aust. N.Z. J. Med., 9, 262–268
Alexanian, R., Fraschini, G. and Smith, L. (1984). Amyloidosis in multiple myeloma or without apparent cause. Arch. Int. Med., 144, 2158–2160
Buckman, R., Cuzick, J. and Galton, D.A. G. (1982). Long-term survival in myelomatosis. Br. J. Haematol., 52, 589–599
Alexanian, R. (1985). Ten year survival in multiple myeloma. Arch. Int. Med., 145, 2073–2074
Jeffries, D.J. (1985). Clinical use of acyclovir. Br. Med. J., 290, 177–178
Harris, D.C.H., Ibels, L.S., Ravich, R.B.M., Isbister, J.P. and Wells, J.V. (1983). Multiple myeloma with renal failure, a case for intensive treatment. Aust. N.Z. J. Med., 13, 163–167
Coward, R. A., Mallick, N. P. and Delamore, I. W. (1983). Should patients with renal failure associated with myeloma be dialized? Br. Med. J., 287, 1575–1578
Medical Research Council working party on leukaemia in adults (1984). Analysis and management of renal failure in fourth MRC myelomatosis trial. Br. Med. J., 288, 1411–1416
Clyne, D. H., Pesce, A. J. and Thompson, R. E. (1979). Nephrotoxicity of Bence Jones Protein in the rat: Importance of protein isoelectric point. Kidney Int., 16, 345–352
Johns, E.A., Turner, R., Cooper, E.H. and MacLennan, I.C.M. (1986). Isoelectric points of urinary light chains in myelomatosis; analysis in relation to nephrotoxicity. J. Clin Pathol., 39, 833–837
Medical Research Council working party on leukaemia in adults (1985). Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br. J. Cancer, 52, 153–158
Bergsagel, D. E. (1985). Controversies in the treatment of plasma cell myeloma. Postgrad. Med. J., 61, 109–116
Hyrniuk, W. and Bush, H. (1986). The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2, 1281–1288
MacLennan I. C. M. (1987). Personal communication.
Barlogie, B., Hall, R., Zander, A., Dicke, K. and Alexanian, R. (1986). High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67, 1298–1301
Selby, P., McElwain, T. J., Nandi, A. A. et a.l (1987). Multiple myeloma treated with high dose intravenous melphalan. Br. J. Haematol., 66, 55–62
Barlogie, B., Smith, L. and Alexanian, R. (1984). Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med., 310, 1353–1356
Alexanian, R., Barlogie, B. and Dixon, D. (1986). High dose glucocorticoid treatment of resistant myeloma. Ann. Int. Med., 195, 8–11
Ohno, R. and Kimara, K. (1986). Treatment of multiple myeloma with recombinant interferon alpha 2a. Cancer, 57, 1685–1688
Case, D.C., Sonneborn, H.C., Paul, S.D. et al. (1986). Phase II study of r-DNA alpha 2 interferon (intron A) in patients with multiple myeloma utilising an escalating induction phase. Cancer Treat. Rep., 70, 1251–1254
Thomas, P. J., Daban, A. and Bontoux, D. (1984). Double hemibody irradiation in chemotherapy resistant multiple myeloma. Cancer Treat. Rep., 68, 1173–1175
Tobias, J. S., Richards, J. D., Blackman, G. M., Joannides, T., Trask, C. W. and Nathan, J. I. (1985). Hemibody irradiation in multiple myeloma. Radiother. Oncol., 3, 11–16
Hobbs, J. R. (1975). Monitoring myelomatosis. Arch. Int. Med., 135, 125–130
Hobbs, J. R. (1971). Mode of escape from therapeutic control in myelomatosis. Br. Med. J., 1, 325
Cohen, H.J., Bartolucci, A.A., Forman, W.B. and Silberman, H. R. (1986). Consolidation and maintenance therapy in multiple myeloma: randomised comparison of a new approach to therapy after initial response to treatment. J. Clin. Oncol., 4, 888–899
Crawford, S. M. (1985). Hypercalcaemia, renal failure and relapse in multiple myeloma. Cancer, 55, 898–900
Bell, E.T. (1933). Renal lesions associated with multiple myeloma. Am. J. Pathol., 9, 393–419
Foord, A. G. and Randall, L. (1935). Hyperproteinaemia, Autohaema-glutination and renal insufficiency in multiple myeloma. Am. J. Clin. Pathol., 5, 532–547
Blackman, S.S., Halsey Barker, W., Buell, M.V. and Davis, B.D. (1944). On the pathogenesis of renal failure associated with multiple myeloma. J. Clin. Invest., 23, 163–166
Rota, S., Mougenot, B., Bandoin, B. et al .(1987). Multiple myeloma and severe renal failure; a clinicopathologic study of outcome and prognosis in 34 patients. Medicine, 66, 126–137
Cohen, A. H. and Border, W.A. (1980). Myeloma kidney: An immuno-morphogenetic study of renal biopsies. Lab. Invest., 42, 248–256
Border, W. A. and Cohen, A. H. (1980). Renal biopsy of clinically silent multiple myeloma. Ann. Int. Med., 93, 43–46
Abrahams, C, Pirani, C.C. and Pollak, V.E. (1966). Ultrastructure of the kidney in a patient with multiple myeloma. J. Pathol Bact., 92, 220–224
Sirota, J. H. and Hamerman, D. (1954). Renal function studies in an adult subject with the Fanconi syndrome. Am. J. Med., 16, 138–145
Maldonado, J. E., Velosa, J. A. and Kyle, R. A. et al. (1975). Fanconi syndrome in adults. Am J. Med., 58, 354–363
Walb, D., Wohlenberg, H., Rampelt, H.J., Schmider, H. and Thomas, L. (1980). Fanconi syndrom des Erwachsenen bei Fruhymelom mit monokloner gammopathie IgG. Typ. Kappa. Deutsche Med. Wochenschrift 195, 1355–1359
Finkel, P. N., Kronentarg, K., Pesce, A. J. et al. (1973). Adult Fanconi syndrome, amyloidosis and marked kappa chain proteinuria. Nephron, 10, 1–24
Rawlings, W., Griffin, J., Duffy, T. and Humphrey, R. (1975). Fanconi syndrome with lambda light chains in urine. N. Engl. J. Med., 292, 1315
De Fronzo, R.A., Cooke, C.R., Wright, J. R. and Humphrey, R.C. (1978). Renal function in patients with multiple myeloma. Medicine (Baltimore), 57, 151–166
Smithline, N., Kassirer, J. P. and Cohen, J. J. (1976). Light chain nephropathy-renal tubular dysfunction associated with light chain proteinuria. N. Engl. J. Med., 294, 71–74
Sanchez, L. M. and Domz, C. A. (1960). Renal patterns in myeloma. Ann. Int. Med 52, 44–54
Lazar, G. S. and Feinstein, D. I. (1981). Distal renal tubular acidosis in multiple myeloma. Arch. Int. Med., 141, 655–657
Forbus, W. D., Perlzweig, W. A. and Parfentier, I. A. (1935). Bence Jones protein excretion and its effects upon the kidney. Bull. Johns Hopkins Hosp., 57, 47–69
Rees, E.G. and Waugh, W. H. (1965). Factors in the renal failure of multiple myeloma. Arch. Int. Med., 116, 400–405
Martinez-Maldonado, M., Yiam, T., Suki, W.N. and Erehogan, G. (1971). Renal complications in multiple myeloma: Pathophysiology and some aspects of clinical management. J. Chron. Dis., 24, 221–237
Schubert, G. E., Veigel, J. and Lennert, K. (1972). Structure and function of kidney in multiple myeloma. Virchow’s Arch. Pathol. Anat., 355, 135–157
Clyne, D.H., Brendstrup, L., First, M.R. et al. (1974). Renal effects of intraperitoneal kappa chain injection. Lab. Invest., 2, 131–142
Beaufils, M. and Morel-Maroger, L. (1978). Pathogenesis of renal disease in monoclonal gammopathies. Current concepts. Nephron, 30, 125–131
Cooper, E. H., Forbes, M. A., Crockson, R. A. and MacLennan, I. C. M. (1984). Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. J. Clin. Pathol., 37, 852–858
Randall, R. E., Williamson, W. C, Mallinson, F., Tuny, M. Y. and Still, W. J. S. (1976). Manifestations of systemic light chain deposition. Am. J. Med., 60, 293–299
Scully, R.E., Galdabini, J. and McNeely, B.U. (1981). Case records of Massachusetts General Hospital. N. Engl. J. Med., 304, 33–43
Seymour, S. E., Thompson, A. J., Smith, P. S., Woodroffe, A.J. and Clarkson, A. R. (1980). Kappa light chain Glomerulosclerosis in multiple myeloma. Am. J. Pathol., 101, 557–580
Soiling, K., Soiling, J. and Jacobsen, O. (1980). Non-secretory myeloma associated with nodular glomerulosclerosis. Acta Med. Scand., 207, 137–143
Van Geelan, J. A. and Mulder, A. W. (1979). Histology and function of the kidney in marked Bence Jones proteinuria. Neth. J. Med., 22, 158–160
Nagengast, F. M., Assmann, K. J. M. and Fennis, J. F. M. (1980). Histology and function of the kidney in marked Bence Jones proteinuria. Neth. J. Med., 23, 38
Koss, M.N., Pirani, C.L. and Osserman, E. F. (1976). Experimental Bence Jones cast nephropathy. Lab. Invest., 34, 579–591
De Fronzo, R.A., Humphrey, R.C., Wright, J. R. and Cooke, C.R. (1975). Acute renal failure in multiple myeloma. Medicine (Baltimore), 54, 209–223
Heyburn, P. J., Child, J. A. and Peacock, M. (1981). Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis. J. Clin. Pathol., 34, 54–57
Vavatsi-Manos, O. and Preuss, H.G. (1976). The effects of high calcium concentrations on renal ammoniagenesis by the kidney slices. Nephron, 17, 474–484
Vanherweghem, J. L., Docobu, J., D’Jollander, A. and Toussaint, C. (1976). Effect of hypercalcaemia on water and sodium excretion by the isolated kidney. Pflug. Arch., 363, 75–80
Nutbeam, H.M., Sinclair, L. and Oberholger, V. G. (1979). Magnesium transport deficit with hypercalcaemia. J. R. Soc. Med., 72, 932–934
Parfitt, A.M. and Kleerekoper, M. (1980). Clinical disorders of calcium phosphorus and magnesium metabolism. In Maxwell, M. H. and Kleeman, C R. (eds.) Clinical Disorders of Fluid and Electrolyte Metabolism, 3rd Edn. (New York: McGraw Hill)
Humes, H.D. (1986). Role of calcium in pathogenesis of acute renal failure. Am. J. Physiol., 250, F579–F589
Epstein, F. H. (1968). Calcium and the kidney. Am. J. Med., 45, 700–714
Takaichi, K., Uchida, S. and Kurokawa, K. (1986). High Ca2+ inhibit a AVP dependent cAMP production in thick ascending limbs of Henle. Am. J. Physiol., 250, F770–7706
Teitelbaum, I. and Berl, T. (1986). Effects of calcium on vasopressin mediated cyclic adenosine monophosphate formation in cultured rat inner medullary tubule cells.J. Clin Invest., 77, 1574–1583
Benabe, J. E. and Martinez-Maldonado, M. (1978). Hypercalaemic nephropathy. Arch. Int. Med., 138, 777–779
Duffy, J. L., Suzuki, Y. and Churg, J. (1971). Acute calcium nephropathy. Arch. Pathol., 91, 340–350
Ganote, C.E., Philipsborn, D.S., Chen, E. and Carone, F.A. (1975). Acute calcium nephrotoxicity. Arch. Pathol., 99, 650–657
Wibbell, L., Dahlberg, P.A. and Karlsson, A. (1974). Hyperparathyroidism associated with distal tubular dysfunction. Acta Med. Scand., 206, 507–510
Revillard, J. P., Manuel, Y., Francois, R. and Traeger, J. (1970). Renal disease associated with tubular proteinuria. In Manuel, Y., Revillard, J. P. and Betael, H. (eds.) Protein in Normal and Pathological Urine (Basel: Karger)
Besarab, A. and Caro, J. (1978). Mechanism of hypercalcaemia in malignancy. Cancer, 41, 2276–2285
Stewart, A.F., Horst, R., Deftos, L.J. et al. (1980). Biochemical evaluation of patients with cancer associated hypercalcaemia. N. Engl. J. Med., 303, 1377–1383
Werner, S. and Low, H. (1977). Urinary excretion of CAMP and GMP in primary hyperparathyroidism with reference to clinical signs and symptoms. Horm. Metab. Res., 9, 332–336
Rude, R. K., Sharp, C F., Fredericko, R. S. et al. (1981). Urinary and nephrogenous adenosine 3′5′ monophosphate in the hypercalcaemia of malignancy. J. Clin. Endothel. Metab., 52, 765–771
Raisz, L.G. (1981). What marrow does to bone. N. Engl. J. Med., 304, 1485–1486
Pootrakul, P., Hungsprenges, S. and Fucharoen, S. (1981). Relation between erythropoiesis and bone metabolism in thalassaemia. N. Engl. J. Med., 304, 1470–1473
Walter, R. M. and Greenberg, B. R. (1980). Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia. Cancer, 46, 1174–1178
Mundy, G. R., Luber, R. A., Raisz, L.G. et al. (1974). Bone resorbing activity in supernatant from lymphoid cell lines. N. Engl. J. Med., 290, 867–871
Mundy, G.R., Raisz, L.G. and Cooper, R.A. et al (1974). Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med., 291, 1041–1046
Josse, R. G., Murray, T. M., Mundy, G. R. et al. (1981). Observations on the mechanisms of bone resorption induced by multiple myeloma culture fluids and partially purified osteoclast activating factor. J. Clin. Invest., 67, 1472–1481
Niel, H. B., Neely, C. L. and Palmieri, G. M. (1981). The postabsorption urinary hydrolyproline (Spot HYPRO) in patients with multiple myeloma. Cancer, 48, 783–787
Mundy, G. R. (1987). The hypercalcaemia of malignancy. Kidney Int., 31, 142–155
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Crawford, S.M. (1989). Multiple Myeloma and Renal Function. In: Catto, G.R.D. (eds) Multisystem Diseases. New Clinical Applications: Nephrology, vol 7. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2223-5_2
Download citation
DOI: https://doi.org/10.1007/978-94-009-2223-5_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7497-1
Online ISBN: 978-94-009-2223-5
eBook Packages: Springer Book Archive